Rapid evolution of resistance to antibiotics represents an increasingly dramatic risk for public health. In fewer than 20 years from now, antibiotic-resistant pathogens could become one of the most frequent causes of unnatural deaths. Medicine is therefore facing the particular challenge of continuing to ensure the successful treatment of bacterial infections - despite an ever-shrinking spectrum of effective antibiotics. Recent research by a group of scientists at Kiel University has now shown that there are possible ways to prolong the effectiveness of the antibiotics that are currently available. The team, headed by Professor Hinrich Schulenburg and Dr. Gunther Jansen from the Evolutionary Ecology and Genetics research group at Kiel University, investigated the effects of daily switching of two pairs of antibiotics that are common in clinical practice against Pseudomonas aeruginosa. This bacterium is a common disease agent, often multi-resistant and can cause life-threatening infections in immunodeficient or chronically ill patients. For the current study, evolution experiments were carried out under controlled laboratory conditions. In doing so, a series of quick switches between the two antibiotics, known as antibiotic cycling, proved highly effective against the pathogen. At the same time, it also inhibited the bacteria's ability to evolve resistance against the drugs. The research group has now published these findings in the current issue of the journal Evolutionary Applications.
Although antibiotic cycling is already widely used in regular medical treatment, antibiotics are usually only switched after several weeks. These time intervals are likely too long. Bacteria are capable of evolving resistance within just a few days - sometimes even within hours. In the evolution experiments, therefore, the scientists now switched clinically relevant antibiotics every 12 hours and compared this treatment to corresponding monotherapies, where a single antibiotic was administered continually.
Quick switching proved particularly effective. "We were surprised that we were able to eliminate bacterial populations in our experiments, despite using non-lethal doses of antibiotics. A temporally complex environment, such as the one created by quickly switching between various antibiotics, seems to overtax the bacterium's ability to evolve any kind of resistance mechanism", says Schulenburg, member of the research focus "Kiel Life Science".
These recent findings by the research group in Kiel therefore indicate a promising alternative approach to conventional use of antibiotics. Their approach has a different rationale and may help to combat the increasingly menacing antibiotics crisis. The focus here is on evolution, and therefore the ability of pathogens to adapt to the antibiotics. "Developing new antibiotic drugs will not be able to keep up with the speed at which pathogens evolve to resist new treatments. Our approach thus aims to apply existing substances more usefully", says Roderich Römhild, lead author of the study.
Further research projects are currently in preparation - paying particular consideration to everyday clinical situations. The available results are part of the Evolutionary Ecology and Genetics research group's ongoing research on pathogen adaptation, which is a central topic within the new research focus "Kiel Life Science" at Kiel University.
More News
GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)
HTGF portfolio company GQ Bio, pioneering a high-capacity adenovirus gene therapy vector platform, was acquired by Pacira BioSciences, Inc. Pacira, the industry leader in its ...
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)
CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and ...
medac has received FDA approval for treosulfan as a new drug application with orphan drug designation prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...